Taysha Gene Therapies (TSHA) Current Leases (2022 - 2026)

Taysha Gene Therapies (TSHA) has 5 years of Current Leases data on file, last reported at $1.8 million in Q1 2026.

• For the quarter ending Q1 2026, Current Leases rose 0.88% year-over-year to $1.8 million; the trailing twelve-month figure through Mar 2026 stood at $1.8 million (up 0.88% YoY), and the FY2025 full-year result was $1.9 million, down 0.64% from the prior year.
• Current Leases slipped to $1.8 million in Q1 2026, from $1.9 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $1.9 million in Q4 2024 to a low of $1.5 million in Q4 2022.
• A 5-year average of $1.7 million and a median of $1.7 million in 2023 frame the typical range for Current Leases.
• Across the five-year window, Current Leases climbed 18.01% in 2024 and retreated 8.1% in 2025, its largest moves.
• Tracing TSHA's Current Leases over 5 years: stood at $1.5 million in 2022, then gained by 8.22% to $1.6 million in 2023, then grew by 14.03% to $1.9 million in 2024, then retreated by 0.64% to $1.9 million in 2025, then decreased by 2.2% to $1.8 million in 2026.
• Business Quant data shows TSHA's Current Leases at $1.8 million in Q1 2026, $1.9 million in Q4 2025, and $1.7 million in Q3 2025.